Announces 2Q of the fiscal year ending January 2027. Revenue is undisclosed; focuses on changes in costs centered on R&D expenses, with an improvement in operating loss. Outlines post-AQUGO (Auguo) launch adoption and strengthened supply chains, accelerated U.S. expansion, and a roadmap toward expanding indications for stroke. <\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4592","jir_company_name":"SBiBio\u682a\u5f0f\u4f1a\u793e","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-17","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4592-20260917-01.pdf","jir_short_summary":"Announces 2Q of the fiscal year ending January 2027. Revenue is undisclosed; focuses on changes in costs centered on R&D expenses, with an improvement in operating loss. Outlines post-AQUGO (Auguo) launch adoption and strengthened supply chains, accelerated U.S. expansion, and a roadmap toward expanding indications for stroke. ","jir_summary":"### Section heading\nThis earnings summary centers on the consolidated results for the 2Q of the fiscal year ending January 2027, outlining current revenue and cost items and the outlook for the second half. It emphasizes post-launch adoption of AQUGO domestically, stabilization of the supply framework, and promotion of regional medical collaboration as a foundation for future global expansion. It explains the reduction in losses due to delayed recognition of some R&D costs, and presents cost plans for H2 and efforts to secure cash position.\n\n### Second section heading\nLooking ahead, the three pillars of a global leader strategy anchored in Japan as the mother base, domestic adoption of AQUGO with expanded U.S. deployment, and expanded indications for stroke are highlighted. It details the reinforcement of regional medical collaboration, integrated manufacturing and logistics, and concrete plans for clinical trial preparations and execution, outlining paths for starting trials and expanding partnerships from next year onward.","jir_financial_highlights":"Business revenue: \uff0d (Unknown)\nBusiness expenses: 1,909 (YoY unknown)\nR&D expenses: 1,226 (YoY \u25b2812 (compared with 2Q FY2027 forecast))\nOperating loss: \u25b21,909 (Actual)\nNet income: \u25b21,791 (Actual)\n$US rate (yen): 159.14 (Change vs prior period)","jir_category":"","jir_hashtags":"#Earnings","jir_key_figures":"Business expenses: 1,909 million yen\nR&D expenses: 1,226 million yen\nNet income: \u25b21,791 million yen","jir_meta_title":"\u3010\u30b5\u30f3\u30d0\u30a4\u30aa\u30112027\u5e741\u6708\u671f2Q\u6c7a\u7b97\u5831\u544a\uff5c\u30a2\u30af\u30fc\u30b4\u666e\u53ca\u3068\u30b0\u30ed\u30fc\u30d0\u30eb\u5c55\u958b\u306e\u5c55\u671b","jir_meta_description":"SBI Biosciences' highlights from the 2Q of the fiscal year ending January 2027. Explains adoption and supply framework reinforcement post-AQUGO launch, progress in U.S. expansion, cost trends in the second half, and upcoming clinical trial plans and growth strategy.","jir_og_title":"SBiBio Earnings Report\uff5cOutlook for AQUGO Adoption and Global Expansion","jir_og_description":"SBiBio's 2Q of the fiscal year ending January 2027. Details adoption and supply framework reinforcement domestically, U.S. expansion, and forthcoming clinical trial plans and growth strategy.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-01\\\",\\\"2026-04\\\",\\\"2026-07\\\",\\\"2026-10\\\",\\\"2027-01\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Business revenue\\\",\\\"data\\\":[0,0,0,0,0]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating profit trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-01\\\",\\\"2026-04\\\",\\\"2026-07\\\",\\\"2026-10\\\",\\\"2027-01\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating profit\\\",\\\"data\\\":[-1888,-1909,0,0,-1909]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Profit margin analysis\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-01\\\",\\\"2026-04\\\",\\\"2026-07\\\",\\\"2026-10\\\",\\\"2027-01\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net income margin\\\",\\\"data\\\":[-1297,-1791,0,0,-1791]}]},\\\"options\\\":{}}\"}]","ir_related_company":9415,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-114818","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n